日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cellular mechanisms of heterogeneity in NF2-mutant schwannoma

NF2 突变型神经鞘瘤的细胞异质性机制

Christine Chiasson-MacKenzie, Jeremie Vitte, Ching-Hui Liu, Emily A Wright, Elizabeth A Flynn, Shannon L Stott, Marco Giovannini, Andrea I McClatchey

Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development

MEK1/2 抑制剂治疗 2 型神经纤维瘤病相关神经鞘瘤的临床前评估揭示了疗效和耐药性发展的差异

Marisa A Fuse, Christine T Dinh, Jeremie Vitte, Joanna Kirkpatrick, Thomas Mindos, Stephani Klingeman Plati, Juan I Young, Jie Huang, Annemarie Carlstedt, Maria Clara Franco, Konstantin Brnjos, Jackson Nagamoto, Alejandra M Petrilli, Alicja J Copik, Julia N Soulakova, Olena Bracho, Denise Yan, Rahul

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1

基因工程小型猪模拟人类 1 型神经纤维瘤病的主要临床特征

Sara H Isakson, Anthony E Rizzardi, Alexander W Coutts, Daniel F Carlson, Mark N Kirstein, James Fisher, Jeremie Vitte, Kyle B Williams, G Elizabeth Pluhar, Sonika Dahiya, Brigitte C Widemann, Eva Dombi, Tilat Rizvi, Nancy Ratner, Ludwine Messiaen, Anat O Stemmer-Rachamimov, Scott C Fahrenkrug, Davi

Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development

Smarcb1 和 Nf2 失活的时间决定了神经鞘瘤与横纹肌瘤的发展

Jeremie Vitte, Fuying Gao, Giovanni Coppola, Alexander R Judkins, Marco Giovannini

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma

mTORC1 抑制可延缓 2 型神经纤维瘤病神经鞘瘤的生长

Marco Giovannini, Nicolas-Xavier Bonne, Jeremie Vitte, Fabrice Chareyre, Karo Tanaka, Rocky Adams, Laurel M Fisher, Laurence Valeyrie-Allanore, Pierre Wolkenstein, Stephane Goutagny, Michel Kalamarides